Article

Acute myeloid leukemia patients with high-risk karyotypes benefit from decitabine in combination with modified CAG

2024-01-08

Abstract excerpt

This study aims to investigate the cytogenetic and molecular characteristics of patients with Acute Myeloid Leukemia (AML) and determine which patients would benefit most from a low-intensity regimen of decitabine in combination with modified CAG (D-CAG) or intensive chemotherapy. We retrospectively analyzed cytogenetic and molecular data from 331 newly diagnosed AML patients and investigated the relationship betw...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 589102dd-ed3d-5a5b-8111-e295b0c5b07b
DOI: 10.21203/rs.3.rs-3823801/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acute myeloid leukemia patients with high-risk karyotypes benefit from decitabine in combination with modified CAGDOI 10.21203/rs.3.rs-3823801/v1Read

[Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].Semantic proximity Read

Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.Semantic proximity Read

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studySemantic proximity Read

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Semantic proximity Read

[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].Semantic proximity Read

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Semantic proximity Read

Single-center retrospective clinical evaluation of venetoclax combined with HMAs and half-dose CAG in the treatment of unfit or refractory/relapsed AMLSemantic proximity Read

Innovative strategies for adverse karyotype acute myeloid leukemia.Semantic proximity Read

The Prognostic Value of RASGEF1A RNA Expression and DNA Methylation in Cytogenetically Normal Acute Myeloid LeukemiaSemantic proximity Read

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Semantic proximity Read

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?Semantic proximity Read

Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMTSemantic proximity Read